Cliff Asness's BMY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 9.46 M shares of Bristol-Myers Squibb Company (BMY) worth $426.35 M, representing 0.27% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 3.4 M shares. Largest reduction occurred in Q3 2019, reducing 4.64 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +436,571 | Add 0.00% | 436,570 | $32.59 |
| Q2 2013 | +329,402 | Add 0.00% | 329,401 | $44.69 |
| Q3 2013 | +1,793 | Add 0.54% | 331,194 | $46.28 |
| Q4 2013 | +152,821 | Add 46.14% | 484,015 | $53.15 |
| Q1 2014 | +90,445 | Add 18.69% | 574,460 | $51.95 |
| Q2 2014 | +422,926 | Add 73.62% | 997,386 | $48.51 |
| Q3 2014 | +137,868 | Add 13.82% | 1.14 M | $51.18 |
| Q4 2014 | -713,475 | Reduce 62.85% | 421,779 | $59.03 |
| Q1 2015 | +53,300 | Add 12.64% | 475,079 | $64.50 |
| Q2 2015 | +888,048 | Add 186.93% | 1.36 M | $66.54 |
| Q3 2015 | +593,640 | Add 43.55% | 1.96 M | $59.20 |
| Q4 2015 | -761,854 | Reduce 38.93% | 1.19 M | $68.79 |
| Q1 2016 | -376,506 | Reduce 31.51% | 818,407 | $63.88 |
| Q2 2016 | -204,936 | Reduce 25.04% | 613,471 | $73.55 |
| Q3 2016 | +201,613 | Add 32.86% | 815,084 | $53.92 |
| Q4 2016 | -405,756 | Reduce 49.78% | 409,328 | $58.44 |
| Q1 2017 | +69,477 | Add 16.97% | 478,805 | $54.38 |
| Q2 2017 | +1.77 M | Add 370.27% | 2.25 M | $55.72 |
| Q3 2017 | +832,608 | Add 36.98% | 3.08 M | $63.74 |
| Q4 2017 | +988,731 | Add 32.06% | 4.07 M | $61.28 |
| Q1 2018 | -729,867 | Reduce 17.92% | 3.34 M | $63.25 |
| Q2 2018 | +1.87 M | Add 55.79% | 5.21 M | $55.34 |
| Q3 2018 | +1.01 M | Add 19.45% | 6.22 M | $62.08 |
| Q4 2018 | +2.3 M | Add 36.95% | 8.52 M | $51.98 |
| Q1 2019 | -18,893 | Reduce 0.22% | 8.5 M | $47.04 |
| Q2 2019 | -820,972 | Reduce 9.66% | 7.68 M | $45.24 |
| Q3 2019 | -4.64 M | Reduce 60.46% | 3.04 M | $50.71 |
| Q4 2019 | +633,429 | Add 20.86% | 3.67 M | $63.63 |
| Q1 2020 | +363,125 | Add 9.89% | 4.03 M | $55.33 |
| Q2 2020 | -625,065 | Reduce 15.50% | 3.41 M | $57.61 |
| Q3 2020 | -184,333 | Reduce 5.41% | 3.22 M | $59.86 |
| Q4 2020 | -391,849 | Reduce 12.15% | 2.83 M | $61.19 |
| Q1 2021 | -80,939 | Reduce 2.86% | 2.75 M | $62.98 |
| Q2 2021 | -738,957 | Reduce 26.86% | 2.01 M | $66.35 |
| Q3 2021 | -454,820 | Reduce 22.60% | 1.56 M | $59.17 |
| Q4 2021 | -31,691 | Reduce 2.03% | 1.53 M | $62.35 |
| Q1 2022 | -79,802 | Reduce 5.23% | 1.45 M | $73.03 |
| Q2 2022 | +119,402 | Add 8.26% | 1.57 M | $76.75 |
| Q3 2022 | +66,803 | Add 4.27% | 1.63 M | $71.09 |
| Q4 2022 | +598,538 | Add 36.67% | 2.23 M | $71.64 |
| Q1 2023 | +511,072 | Add 22.91% | 2.74 M | $69.07 |
| Q2 2023 | +168,024 | Add 6.13% | 2.91 M | $63.95 |
| Q3 2023 | -654,731 | Reduce 22.50% | 2.26 M | $58.04 |
| Q4 2023 | -153,229 | Reduce 6.80% | 2.1 M | $51.31 |
| Q1 2024 | +246,701 | Add 11.74% | 2.35 M | $53.85 |
| Q2 2024 | +327,824 | Add 13.96% | 2.68 M | $41.53 |
| Q3 2024 | +1.22 M | Add 45.73% | 3.9 M | $51.40 |
| Q4 2024 | +106,630 | Add 2.73% | 4.01 M | $56.56 |
| Q1 2025 | +1.96 M | Add 48.97% | 5.97 M | $60.99 |
| Q2 2025 | +98,910 | Add 1.66% | 6.07 M | $46.26 |
| Q3 2025 | +3.4 M | Add 55.97% | 9.46 M | $45.05 |
Cliff Asness's Bristol-Myers Squibb Company Investment FAQs
Cliff Asness first purchased Bristol-Myers Squibb Company (BMY) in Q4 2012, acquiring 436,570 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Bristol-Myers Squibb Company (BMY) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Bristol-Myers Squibb Company (BMY) was in Q3 2025, adding 9,463,981 shares worth $426.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 9,463,981 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $426.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.27% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Bristol-Myers Squibb Company (BMY) was 9,463,981 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.